Main menu


You are here

Treatments

Paxlovid cuts hospitalization, death only in COVID patients with weak immune systems -- Canadian study

 

...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.

...

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

US judge rules against blocking Medicare from negotiating drug prices

US judge refuses to block Medicare from negotiating drug prices | Reuters

Sept 29 (Reuters) - The U.S. government's Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of President Joe Biden's signature initiatives.

The order by U.S. District Judge Michael Newman in Dayton, Ohio, comes in a lawsuit brought against the Biden administration by the U.S. Chamber of Commerce.

...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Both Paxlovid, molnupiravir lower COVID Omicron deaths, hospitalizations -- studies

Two new studies describe the benefits of the antiviral drugs nirmatrelvir-ritonavir (Paxlovid) and molnupiravir in reducing SARS-CoV-2 Omicron hospitalizations and death, with one finding that the former is more effective than the latter at lowering death rates.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Depressant fluvoxamine not effective in reducing COVID inflammation--study

 

A clinical trial designed to test repurposed medications for their impact on fighting COVID-19 has found no benefit to taking the antidepressant fluvoxamine (Luvox) to ease coronavirus symptoms.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Treatments
howdy folks
Page loaded in 0.564 seconds.